Mergers & Acquisitions ·
Ensysce completes acquisition of Cy Biopharma for $21.5M private placement
ENSCEnsysce Biosciences, Inc.
On August 5, 2026, Ensysce Biosciences completed its acquisition of Cy Biopharma pursuant to a merger agreement. As consideration, Ensysce issued Series C Preferred Stock convertible into common stock and raised approximately $21.5 million in gross proceeds through a concurrent private placement of additional Series C shares. The transaction expands Ensysce's pipeline to include Cy Biopharma’s neuroplastogenic therapies for severe chronic pain, specifically psilocybin-based candidates CY200 and CY201 for Complex Regional Pain Syndrome (CRPS). Ensysce is a clinical-stage pharmaceutical company developing abuse-resistant opioid prodrugs and novel pain treatments.